Barclays raised the firm’s price target on Revolution Medicines to $60 from $54 and keeps an Overweight rating on the shares. Positive for stock would be RMC-6236 showing progression free survival of eight months along with clean safety profile in G12X non-small cell lung cancer, the analyst tells investors in a research note. The firm sees 70% likelihood for positive data. The higher price target reflects increased duration of treatment estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines participates in a conference call with JPMorgan
- Revolution Medicines added to Analyst Focus List at JPMorgan
- 3 Best Stocks to Buy Now, 9/18/2024, According to Top Analysts
- Revolution Medicines added to Analyst Current Favorites list at Raymond James
- Revolution Medicines Appoints Frank Clyburn to Expanded Board
Questions or Comments about the article? Write to editor@tipranks.com